Trial Profile
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Carbamazepine (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- Sponsors Validus Pharmaceuticals
- 01 Mar 2023 Status changed from completed to discontinued due to no apparent therapeutic effects that was superior to placebo.
- 27 Feb 2023 Status changed from recruiting to completed.
- 07 Jan 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.